Aixial acquires Cmed Group


Purchase of technology-powered CRO grows Aixial's offerings in clinical operations and product development

France-based Aixial, the CRO of Alten Group, has acquired UK portfolio company Cmed Group by Alten Europe, an engineering and technology consultant. Cmed is a technology-led CRO that specializes in full-service oncology, immuno-oncology, cell therapy and rare diseases, and the delivery of data and analytic services. Cmed also has a tech division that developed Encapsia, a clinical data suite purpose created to support traditional, decentral, virtual and hybrid clinical trials.

Cmed has provided biopharma and medical device partners across the globe with clinical operations, data sciences and analytics, regulatory affairs, pharmacovigilance and product development services, for more than two decades.

By partnering with Aixial, the combined group now has widespread geographical coverage, with the capability to support customers with a wide range of expertise and solutions. Clients will benefit, executives say, from the ability to quickly and dependably scale, while Encapsia will be enhanced to allow customers to have services and technology improved to deliver various types of clinical trials.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.